Dublin, Oct. 26, 2017 -- The "R&D Drug Pipeline Database" newsletter has been added to Research and Markets' offering.
R&D Drug Pipeline Database: 1-Year Subscription
Subscription to La Merie Publishing's proprietary R&D Drug Pipeline Database provides 24/7 online access to information about more than 21,000 project entries (files) for therapeutic drugs on the market and on investigational drug candidates in research & development.
Pre-established and free search functions allow to identify molecules according to their:
- Product category (NCE, antibodies, proteins, DNA, RNA, cells, vaccines, peptides)
- Technology (e.g. antibody-drug conjugate, bispecific antibody)
- Target (e.g. Her2, Amyloid beta, TNF, PD-1/PD-L1)
- Pipelines (selected by target, therapeutic area, company, technology)
- Sales (for marketed antibodies, peptides and proteins)
- R&D Phase (clinical phases, market, preclinical)
- Territory (countrywise)
- Therapeutic Area (e.g. infectious, oncology, gastrointestinal)
- Drug Code/Name (for individual molecules)
Each project is specified for its Target, Therapeutic Area and R&D Phase. Use of the R&D Drug Pipeline Database is intuitive. Data sets of interest can be printed and exported as reports in Excel or Word format. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major therapeutic antibodies, proteins and peptides on the market are provided.
An advanced search function allows to combine search parameters. A scroll down menu for predefined targets and technologies conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase or company name.
Special Focus of the Database:
- Antibodies
- Proteins
- Peptides
- Vaccines
Purchase of the subscription provides a 1-year online access to the data of the R&D Drug Pipeline Database. Credentials to access the database will be sent by e-mail within 24 hours after purchase.
Benefits from the R&D Drug Pipeline Database:
- Intuitive use
- 24/7 online access
- Designed for structured searches
- Focused on targets, product categories and R&D phases
- Ideal for competitor analysis (companies, targets, product categories)
- Cost-effective and rapid solution for benchmarking
- Identification of licensing candidates
Project listing in a tabular format:
- Drug Codes
- Target/Mechanism of Action
- Class of Compound
- Product Category
- Company
- Territory
- Therapeutic Area
- Indication
- R&D Phase
Product Categories:
- Antibody
- Cell
- DNA
- Peptide
- Protein
- RNA
- Small Molecule
- Vaccine
Therapeutic Areas:
- Cardiovascular, blood & acute care
- Dermatology
- Gastrointestinal
- Genitourinary, gynecology & renal
- Infectious & toxicology
- Metabolism & endocrine
- Neurology & psychiatry
- Oncology
- Ophthalmolgoy & otorhinolaryngology
- Orthopedics, dental, anesthesia & surgery
- Pulmonary & respiratory
- Rheumatoid & autoimmune
Examples of Predefined Targets of the Scroll Down Menu:
- Antibody-Drug Conjugates (ADC)
- Sales of Antibodies & Proteins 2015
- CAR & TCR Engineered T-Cells and NK Cells
- Adalimumab (Humira) Biosimilars
- Her2 Antibodies
- Amyloid beta-Targeted Antibodies
- CD10-Targeted Immunotherapeutics
- Immunocytokines
- Bispecific Antibodies
- Peptide Sales 2015
- PD-1 & PD-L1 Immune Checkpoint Inhibitors
- Zika Virus Vaccines
- Coagulation Factors
- Botulinum Neurotoxins
- Human Papilloma Virus (HPV) Vaccines & Therapeutics
- G-CSF & GM-CSF
- PTH-R Agonists
- Cardiometabolic Peptides
- Immune Checkpoint Modulators
Examples of Predefined Technologies of the Scroll Down Menu:
- Transgenic XenoMouse Antibodies
- T-Cell Redirecting Bispecific Antibodies
- ADC - Pyrrolobenzodiazepine (PBD)
- Fc-Fusion Proteins
- Oligo- and Polyclonal Antibodies
For more information about this newsletter visit https://www.researchandmarkets.com/research/7lcs34/randd_drug
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Drug Discovery


Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S.
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S.
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 



